• 1
    Renshaw A. Measuring sensitivity in gynecologic cytology: a review. Cancer (Cancer Cytopathol). 2002; 96: 210217.
  • 2
    Koss LG. The Papanicolaou test for cervical cancer detection. JAMA. 1989; 261: 737743.
  • 3
    Devesa SS, Young JL. Recent trends in cervix uteri cancer. Cancer. 1989; 64: 21842190.
  • 4
    Perey R. Cervical cancer and the misdiagnosed Pap smear. Law Office of Ron Perey Trial Lawyers (newsletter), March 1997.
  • 5
    McCrory DC, Mather DB, Bastian L, et al. Evaluation of cervical cytology. Evidence Report/Technology Assessment No.5. Rockville (MD): Agency for Health Care Policy and Research; 1999 AHCPR Pub. No. 99-EO10.
  • 6
    Colgan TJ, Austin RM, Davey DD. The annual Papanicolaou test, women's safety and public policy. Cancer (Cancer Cytopathol). 2001; 93: 8185.
  • 7
    Kinney W, Miller M, Sung HY, Sawaya GF, Kearney KA, Hiatt RA. Risk of invasive squamous carcinoma of the cervix associated with screening intervals of 1, 2, and 3 years: a case-control study. Obstet Gynecol. 2001; 97: 3S.
  • 8
    Van den Akker-van Marle ME, van Ballegooijen MV, van Oartmarssen GJ, Boer R, Habbema JDF. Cost-effectiveness of cervical cancer screening. Comparison of screening policies. J Natl Cancer Inst. 2002; 94: 193204.
  • 9
    Austin RM. Who should decide how effective cervical cancer screening should be? J Reprod Med. 1999; 44: 317320.
  • 10
    Davison JM, Marty JJ. Detecting premalignant cervical lesions. Contributions of screening colposcopy to cytology. J Reprod Med. 1994; 39: 388392.
  • 11
    Baldauf JJ, Dreyfus M, Lehmann M, Ritter J, Phillipe E. Cervical cancer screening with cervicography and cytology. Eur J Obstet Gynecol Reprod Biol. 1995; 58: 3339
  • 12
    Hockstad RL. A comparison of simultaneous cervical cytology, HPV testing, and colposcopy. Fam Pract Res J. 1992; 12: 5360,.
  • 13
    Friedell GH. Addendum. In: SommersSC, editor. Genital and mammary pathology decennial. New York: Appleton-Century-Crofts, 1975: 4953.
  • 14
    Hutchinson ML, Zahniser DJ, Sherman ME, et al. Utility of liquid-based cytology for cervical carcinoma screening. Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer (Cancer Cytopathol). 1999; 87: 4855.
  • 15
    Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: a cross sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83: 439444.
  • 16
    Wright TC, Cox JT, Massad ES, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytologic abnormalities. JAMA. 2002; 287: 21202129.
  • 17
    Schiffmanm M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening results from women in a high risk province in Costa Rica. JAMA 2000; 283: 8793.
  • 18
    Brown AD, Raab SS, Suba EJ, Wright RG. Cost-effectiveness studies on cervical cancer. Acta Cytol. 2001; 45: 509514.
  • 19
    Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995; 85: 791794.
  • 20
    Smith HO, Tiffany MF, Qualls CR, Key CR. The Rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24 year population-based study. Gynecol Oncol. 2000; 78: 97105.
  • 21
    Cox JT. AGUS Pap smears. A follow-up strategy. Obgyn Manage. 1998; 27: 7487.
  • 22
    Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong benefit. Br J Cancer. 1995; 71: 894897.
  • 23
    Bergstrom R, Sparen P, Adami H-O. Trends in cancer uteri in Sweden following cytologic screening. Br J Cancer. 1999; 81: 159166.
  • 24
    Brinton LA, Tashima KT, Lehman HF, et al. Epidemiology of cervical cancer by cell type. Cancer Res. 1987; 47: 17061711.
  • 25
    Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000; 23: 1924.
  • 26
    Ronnett BM, Manos MM, Ransley JE, et al. Atypical glandular cells of undetermined significance (AGCUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol. 1999; 30: 816825.
  • 27
    Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol. 1999; 180: 571577
  • 28
    Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical cells of undetermined significance. JAMA. 2002; 287: 23822390.
  • 29
    Solomon D, Schiffmann M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. J Natl Cancer Inst. 2001; 93: 293299.
  • 30
    Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a College of American Pathologists Q-Probes Study of 16,132 cases from 306 laboratories. Arch Pathol Lab Med. 2000; 124: 665671.